← Back to patent-cliff list
Naftopidil
Tier C — Watch / tradeNaftopidil
F. Hoffmann-La Roche
Originator
1998
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRA1
Brand：Avishot, Flivas, Eapidil
Indications (approved)：排尿困难, Benign prostatic hyperplasia
Regional status
US
-
EU
-
China
Approved
2001-01-01
Japan
Approved
1998-12-25
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Naftopidil?
Approved indications include: 排尿困难, Benign prostatic hyperplasia.
When does the Naftopidil patent expire?
No public expiry year is available for Naftopidil yet; this page updates once verified.
How do I get a quote for Naftopidil intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27